Mads H. Haugen

1.8k total citations · 1 hit paper
40 papers, 1.2k citations indexed

About

Mads H. Haugen is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Mads H. Haugen has authored 40 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 22 papers in Cancer Research and 20 papers in Oncology. Recurrent topics in Mads H. Haugen's work include Protease and Inhibitor Mechanisms (13 papers), Peptidase Inhibition and Analysis (7 papers) and HER2/EGFR in Cancer Research (6 papers). Mads H. Haugen is often cited by papers focused on Protease and Inhibitor Mechanisms (13 papers), Peptidase Inhibition and Analysis (7 papers) and HER2/EGFR in Cancer Research (6 papers). Mads H. Haugen collaborates with scholars based in Norway, Germany and United States. Mads H. Haugen's co-authors include Gunhild M. Mælandsmo, Solveig Pettersen, Klaudia Brix, Kjersti Flatmark, Rigmor Solberg, Harald Thidemann Johansen, Arne Klungland, Sebastian Preißl, Rajikala Suganthan and Ah Young Lee and has published in prestigious journals such as Nature, PLoS ONE and Cancer Research.

In The Last Decade

Mads H. Haugen

38 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Broad histone H3K4me3 domains in mouse oocytes modulate maternal-to-zygotic transition

2016 450 citations Mads H. Haugen et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mads H. Haugen Norway	18	856	320	227	132	109	40	1.2k
Camilla Furu Skjelbred Norway	18	840 1.0×	242 0.8×	229 1.0×	70 0.5×	111 1.0×	31	1.2k
Carlo Stresemann Germany	13	1.7k 2.0×	605 1.9×	187 0.8×	130 1.0×	76 0.7×	15	2.0k
Jaira F. de Vasconcellos United States	14	549 0.6×	167 0.5×	136 0.6×	162 1.2×	43 0.4×	33	910
Rocco Palermo Italy	24	849 1.0×	234 0.7×	237 1.0×	186 1.4×	98 0.9×	38	1.2k
Maria Svetlova Russia	17	807 0.9×	262 0.8×	181 0.8×	63 0.5×	70 0.6×	40	1.1k
Annalisa Lonetti Italy	24	824 1.0×	179 0.6×	251 1.1×	157 1.2×	411 3.8×	57	1.5k
Alicia A. Goyeneche Canada	19	429 0.5×	205 0.6×	293 1.3×	178 1.3×	110 1.0×	43	1.2k
Paola Ferraro Italy	24	1.2k 1.4×	135 0.4×	222 1.0×	153 1.2×	28 0.3×	32	1.6k
Jeff Lightfoot Canada	10	728 0.9×	279 0.9×	141 0.6×	119 0.9×	59 0.5×	15	925
Alihossein Saberi Iran	13	1.1k 1.3×	291 0.9×	464 2.0×	71 0.5×	43 0.4×	62	1.5k

Countries citing papers authored by Mads H. Haugen

Since Specialization

Citations

This map shows the geographic impact of Mads H. Haugen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mads H. Haugen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mads H. Haugen more than expected).

Fields of papers citing papers by Mads H. Haugen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mads H. Haugen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mads H. Haugen. The network helps show where Mads H. Haugen may publish in the future.

Co-authorship network of co-authors of Mads H. Haugen

This figure shows the co-authorship network connecting the top 25 collaborators of Mads H. Haugen. A scholar is included among the top collaborators of Mads H. Haugen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mads H. Haugen. Mads H. Haugen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Parissenti, Amadeo M., et al.. (2025). High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy. Breast Cancer Research. 27(1). 143–143.

Fleischer, Thomas, Mads H. Haugen, Laxmi Silwal‐Pandit, et al.. (2024). An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer. Molecular Oncology. 18(8). 2042–2059. 3 indexed citations

Pettersen, Solveig, Abhilash Pandya, Mads H. Haugen, et al.. (2024). The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy. British Journal of Cancer. 131(10). 1656–1667. 7 indexed citations

Haugen, Mads H., Vesa Hongisto, Miriam R. R. Aure, et al.. (2023). High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer. PLoS ONE. 18(1). e0280507–e0280507. 5 indexed citations

Haugen, Mads H., Abhilash Pandya, Lise‐Lotte Vedin, et al.. (2023). Liver X receptors induce antiproliferative effects in basal‐like breast cancer. Molecular Oncology. 17(10). 2041–2055. 2 indexed citations

Nygaard, Vigdis, Anne Hansen Ree, Vegar Johansen Dagenborg, et al.. (2023). A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases. Cancer Research Communications. 3(2). 235–244. 3 indexed citations

Haugen, Mads H., et al.. (2022). miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy. Breast Cancer Targets and Therapy. Volume 14. 25–39. 13 indexed citations

Halvorsen, Ann Rita, Mads H. Haugen, Marius Lund‐Iversen, et al.. (2020). Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients. Frontiers in Oncology. 10. 590755–590755. 4 indexed citations

Flem‐Karlsen, Karine, Mads H. Haugen, Hans Petter Gullestad, et al.. (2019). Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma. Molecular Cancer Therapeutics. 19(3). 895–905. 19 indexed citations

10.

Aure, Miriam R. R., Mads H. Haugen, Kristine Kleivi Sahlberg, et al.. (2019). miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer. Molecular Oncology. 13(10). 2278–2296. 38 indexed citations

11.

Haugen, Mads H., Ole Christian Lingjærde, Oslo Garred, et al.. (2019). Design of a protein signature predicting response to neo-adjuvant treatment with chemotherapy combined with bevacizumab in breast cancer patients. Annals of Oncology. 30. iii8–iii8.

12.

Hilmarsdóttir, Bylgja, Jana Kim, Mads H. Haugen, et al.. (2019). Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer. Breast Cancer Research. 21(1). 61–61. 49 indexed citations

13.

Jørgensen, Kjetil Nordbø, Marco Albrecht, Mads H. Haugen, et al.. (2018). Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment. Cancer Letters. 439. 1–13. 6 indexed citations

14.

Haugen, Mads H., Solveig Pettersen, Wioletta Rut, et al.. (2017). Glycosylation is important for legumain localization and processing to active forms but not for cystatin E/M inhibitory functions. Biochimie. 139. 27–37. 23 indexed citations

15.

Hetland, Geir, Dag M. Eide, Jon Magnus Tangen, et al.. (2016). The Agaricus blazei-Based Mushroom Extract, Andosan™, Protects against Intestinal Tumorigenesis in the A/J Min/+ Mouse. PLoS ONE. 11(12). e0167754–e0167754. 14 indexed citations

16.

Fleten, Karianne G., Anna Barkovskaya, Vigdis Nygaard, et al.. (2016). Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors. Oncotarget. 7(15). 19997–20015. 25 indexed citations

17.

Tamhane, Tripti, et al.. (2015). Construction of a plasmid coding for green fluorescent protein tagged cathepsin L and data on expression in colorectal carcinoma cells. Data in Brief. 5. 468–475. 3 indexed citations

18.

Tamhane, Tripti, et al.. (2015). Nuclear cathepsin L activity is required for cell cycle progression of colorectal carcinoma cells. Biochimie. 122. 208–218. 54 indexed citations

19.

Haugen, Mads H., Harald Thidemann Johansen, Solveig Pettersen, et al.. (2013). Nuclear Legumain Activity in Colorectal Cancer. PLoS ONE. 8(1). e52980–e52980. 71 indexed citations

20.

Smith, Robert L., Harald Thidemann Johansen, Hilde Nilsen, et al.. (2012). Intra- and extracellular regulation of activity and processing of legumain by cystatin E/M. Biochimie. 94(12). 2590–2599. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact